MGNX logo

MGNX MacroGenics, Inc.

NASDAQ · Biotechnology · Healthcare

$1.96
-0.02 (-1.01%)

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tria…

Market Cap: $125.26Mwww.macrogenics.com

Price

No data yet.

Social Signal Score

42
5d
—
30d
50
1 mentions
—
60d
35
3 mentions
—
90d
42
5 mentions
—
news: 5

Analyst Ratings

22 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 9Sell 1Strong Sell 0
Avg price target$6+206.1%
Low $6Median $6High $6
Current Consensus

Revenue

$18.67M+96.99%
$1.08M$52.15M$103.23M$154.31M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.09
$-1.77–$-0.69
3 analysts
FY2026
$-1.61
$-2.01–$-1.22
2 analysts
FY2027
$-1.79
$-2.05–$-1.45
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Eric Risser
Sector
Healthcare
Industry
Biotechnology
Employees
293
Beta
1.32
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-5.61
www.macrogenics.com